|
|
|
|
|
|
|
|
|
sponsored by
|
|
|
|
Moving beyond innovation for ADC success
|
| Innovation alone isn’t enough. Antibody-drug conjugates require alignment across dosing, biomarkers and global trial strategy to move programs forward with greater speed and confidence. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A senior FDA official is joining us at the US Pharma and Biotech Summit next week. US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. You won't want to miss this conversation. Join us in NYC or virtually here. |
|
|
|
Alex Hoffman |
Senior Copy Editor, Endpoints News
|
|
|
|
|
|
|
by Lei Lei Wu
|
EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The... | |
|
|
|
|
|
|
by Max Gelman
|
There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase... | |
|
|
|
|
|
|
|
|
by Kyle LaHucik
|
Blackstone Life Sciences, fresh off one of the largest private investment fundsin industry history, is putting $250 million to work on a little-known biotech... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reportedinitial data in six patients who received the low
dose... | |
|
|
|
